Astellas Pharma

Enfortumab vedotin (Padcev) is an antibody-drug conjugate that targets Nectin-4, a protein found on bladder cancer cells. It delivers a cancer-killing drug directly to those cells. It is used alone or with pembrolizumab to treat certain types of bladder and urinary tract cancers.

Enfortumab vedotin is made of two parts: an antibody that finds bladder cancer cells, and a cancer-killing drug attached to it. The antibody binds to

Xtandi (enzalutamide) is an androgen receptor inhibitor from Astellas for prostate cancer. It blocks androgen binding, receptor activation and nuclear signalling in one drug, and is used across castration-resistant and hormone-sensitive disease settings.

Prostate cancers usually depend on male hormones acting through the androgen receptor. Enzalutamide blocks the receptor itself: it stops androgens fro